Evidence map›Paper›PMID 40999989›Full record

ArticleInternational journal of molecular medicine2025

Cynarin as a potent anti‑osteolytic agent: Targeting MAPK and Nrf2‑Keap1 pathways for osteoclast inhibition and bone protection.

Rui Chao, Yexin Wang, Zhan Liu, Tianhao Wan, Yi Mao, Xinru Xie, Lei Sun, Weifeng Xu, Xuzhuo Chen, Shanyong Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rui Chao *Department of Oral Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China.
Yexin Wang *Department of Oral Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China.
Zhan Liu *Department of Oral Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China.
Tianhao WanDepartment of Oral Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China.
Yi MaoDepartment of Oral Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China.
Xinru XieDepartment of Oral Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China.
Lei SunDepartment of Stomatology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230601, P.R. China.
Weifeng XuDepartment of Oral Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China.
Xuzhuo ChenDepartment of Oral Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China.
Shanyong ZhangDepartment of Oral Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bone resorption, especially bone loss caused by the abnormal activation of osteoclasts (OCs), has become an increasing health concern. As a natural anti‑inflammatory compound, cynarin has shown potential in the treatment of various inflammatory diseases; however, its role in inflammatory bone resorption remains to be investigated. The present study aimed to explore the therapeutic potential of cynarin in inflammatory bone resorption by focusing on its regulatory effects on OC differentiation, inflammatory responses and related signalling pathways. Our results showed that cynarin significantly inhibited bone resorption, reduced tartrate‑resistant acid phosphatase activity, and downregulated key OC differentiation markers (

Indexed as

Kelch-Like ECH-Associated Protein 1MAP Kinase Signaling SystemNF-E2-Related Factor 2OsteoclastsOsteolysisAnimalsBone ResorptionCell DifferentiationMaleMiceMitogen-Activated Protein KinasesOsteogenesisRAW 264.7 CellsSignal TransductionKeap1 protein, mouseKelch-Like ECH-Associated Protein 1Mitogen-Activated Protein KinasesNfe2l2 protein, mouseNF-E2-Related Factor 2cynarininflammationMAPKNrf2osteoclastogenesisosteolysis

Identifiers

PMID40999989
PMCPMC12488209

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.